Friday, 5 June 2020

Global Biosimulation Market 2020 Business Insights & Deep Analysis to 2025 by World’s Top 10 Key Players

According to MRFR analysis, Biosimulation Market is expected to register a CAGR of 15.9% during the forecast period of 2019 to 2025 and is likely to be valued at USD 4.4 Billion by 2025.  
Biosimulation is a tool used for the prediction of the outcomes of existing clinical trials associated with innovation and new drug development.
The growth of the Global Biosimulation Market is determined by numerous factors such as the growing adoption of biosimulation software by regulatory bodies, increasing healthcare expenditure, increasing use of pharmacokinetic & pharmacodynamic modeling in pre-clinical development and rising need to reduce the drug development costs. However, lack of standardization in biosimulation methodology and lack of trained professionals for monitoring biosimulation software are likely to hamper the growth of the global biosimulation market during the forecast period.  
Several market players currently dominate the Global Biosimulation Market. The key players are involved in product launches and strategic collaborations to strengthen their market positions. For instance, in September 2019, Certara Inc. launched version 8.2 of Phoenix, the most advanced and widely used validated software for PK, PD, and toxicokinetic modeling and simulation worldwide.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
Americas has been segmented into North America and Latin America, with the North American market being divided into the US and Canada. The Americas is projected to hold the largest market share owing to the increasing R&D spending by pharmaceutical and biotechnology companies in the region and growing number of clinical trials & drug development practices.  
The European biosimulation market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The biosimulation market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Rising geriatric population and the presence of a large patient pool, are the key factors responsible for the fastest growth of the market in Asia-Pacific. The biosimulation market in the Middle East & Africa has been divided into the Middle East and Africa.
Segmentation
The Global Biosimulation Market has been segmented based on product, application, delivery model and end users.
The market, based on product, has been divided into software and services. The software segment is further segmented into PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation software, molecular modeling and simulation software, PBPK (physiologically based pharmacokinetic) modeling and simulation software, toxicity prediction software, trial design software, and others. The services segment is further segmented into in-house services and contract services. The software segment is likely to hold the maximum market share in the global biosimulation market owing to growing adoption of biosimulation software by pharmaceutical and research organizations and the increasing R&D investment for pharmaceutical research.
The global biosimulation market based on the application has been segregated into drug development, drug discovery, and others. The drug development segment is expected to hold a larger share of the market share owing to the rising adoption of biosimulation tool for the drug development process.
The delivery model segment of the market is divided into subscription models and ownership models.
Based on end users, the global biosimulation market has been segmented into pharmaceutical and biotechnology companies, contract research organizations, research institutes, regulatory authorities, and others. Rising adoption of inorganic growth strategies by different biosimulation service providers is likely to boost the adoption of biosimulation solutions in the pharmaceuticals and biotechnology companies.
Key Players
Some of the Key Players in the Global Biosimulation Market are Dassault Systèmes (France), Certara USA, Inc. (US), Simulation Plus (US), Schrödinger (US), Chemical Computing Group (Canada), Physiomics (UK), In Silico Biosciences (US), Advanced Chemistry Development, Inc. (Canada), Genedata AG (Switzerland), Nuventra Pharma (US), Evidera (US), Leadinvent Technologies (India), LeadScope, Inc. (US), Rosa (US) and INOSIM Software GmbH (Germany).
Posted by at No comments:

Physical Therapy Equipment Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2025

Market Scenario:
There has been a high level of technological improvement in physical therapy equipment in the past few years, which is fueling the global market growth. Also, as physical therapy equipment is designed specifically to assist people to either regain or improve their physical abilities; thus, number of companies are investing in this market.
The Global Physical Therapy Equipment Market is expected to hold a value of USD 19,100 Million by 2025 at a CAGR of 6.21%, says Market Research Future in Physical Therapy Equipment Market Forecast 2020.
Market Influencer
The increasing initiatives by public and private companies boost market growth. The growing number of equipment launches also acquisitions and mergers of key players in the market are likely to act as a promising factor for the growth in the near future.  For instance, in February 2019, Colfax acquired DJO Global, Inc. for USD 3.15 billion. This helps Colfax to widen its product portfolio in the orthopedic segment.
Market Drivers
  • Growing prevalence of orthopedic disorders
  • Rising geriatric population
  • Rising incidence of sport injuries
  • Increasing awareness about physical therapy equipment
  • Rising incidences of road accidents
  • Huge number of R&D activities in the field of physiotherapy
  • Upsurging support by public and private companies
  • Increasing mergers and acquisitions by prominent players in the market. For instance, in April 2017, Dynatronics’s acquired Hausmann Industries, a manufacturer of branded, high-quality physical therapy and athletic training products. With this acquisition, the company aimed to increase business in the physical therapy equipment market
  • Growing government schemes promoting the use of rehabilitation equipment
Market Restraints
  • Inadequate reimbursement policies for physiotherapy
  • Lack of trained and skilled personnel
Segmentation
By Product
  • Equipment: Expected to hold the largest share, owing to the wide range of applications it offers. The type of equipment is electrotherapy equipment, ultrasound equipment, exercise therapy equipment, cryotherapy equipment, combination therapy equipment, continuous passive motion (CPM) therapy equipment, shockwave therapy equipment, laser therapy equipment, traction therapy equipment, magnetic therapy equipment, and others.
  • The use of physical therapy equipment is increased due to the global increase in orthopedic diseases. For example, approximately 80% of Americans will experience back problems at some point in their lives.  Also, an estimated 10% of the world’s population suffers from lower back pain.
  • Accessories: This is expected to be the fastest segment attributed to increasing use of physical therapy equipment for the cure of musculoskeletal diseases. The accessories segment is further divided into two types, namely, physiotherapy furniture and physiotherapy tapes and bandages.
By Application
  • Musculoskeletal Applications: Expected to hold the largest share, owing to increasing incidence of musculoskeletal disorders and also increasing the geriatric population.
  • Neurological Applications: This is expected to hold the fastest segment is attributed to an increase in prevalence of neurological diseases such as paralytic attacks and strokes.
  • Cardiovascular & Pulmonary Applications: The cardiovascular and pulmonary applications segment is witnessing significant growth due to increasing prevalence of cardiovascular diseases and chronic obstructive pulmonary disease (COPD).
  • Pediatric Applications: Increased use of physical therapy for musculoskeletal (MSK) disorders in children.
  • Gynecological Applications: The role of physiotherapy is in obstetrics and gynecology involves pregnancy, labor, and the puerperium, preoperative, and postoperative periods.
  • Others: Other applications include rehabilitation centers where the use of physical therapy is increasing.
By End-User
  • Hospitals and Clinics: Hospitals and clinics are expected to hold the largest segment due to usually a large patient pool and advanced physical therapy setups in hospitals based on the need of patients. Growing awareness about new physical therapy is projected to drive the growth of this segment during the forecast period.
  • Physiotherapy Centers: Expected to hold the fastest segment, owing to growing awareness about new physical therapy among the population.
  • Home Care Settings: Many companies launching the range of physical therapy devices available for use at home.
By Region
  • Americas: The largest regional market. Countries such as the US and Canada have well-established physical therapy centers which constitute advanced physical therapy systems and instruments. This contributes to the growth of the physical therapy equipment market in this region.
  • Europe: The Europe market is expected to hold the second-largest market due to increasing prevalence of neurological disorders, orthopedic problems coupled with cardiopulmonary diseases in the region.
  • Asia-Pacific: The Asia-Pacific region is anticipated to be the fastest-growing region in the global physical therapy equipment market. This is due to the increasing geriatric population and a large number of patients suffering from neurological diseases in China and Japan.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.
Key Players
  • DJO Global, Inc. (US)
  • BTL Industries (US)
  • Enraf-NoniUS B.V (Europe)
  • Dynatronics Corporation (US)
  • EMS Physio (UK)
  • ITO Co. Ltd (Japan)
  • Mectronic Medicale (Europe)
  • Performance Health (Subsidiary of Madison Dearborn Partners) (US)
  • Whitehall Manufacturing (US)
  • Zimmer Medizinsysteme GmbH (Germany)
  • Colfax Corporation (US)
  • STORZ MEDICAL (US)
Posted by at No comments:

Medical Writing Market Covering Growth Inclinations & Development Strategies until 2025

Market Research Future (MRFR) has announced a new release on the global Medical Writing market. The report takes into account the global Medical Writing market’s historical growth trajectory and major growth drivers and restraints in order to come up with a reliable projection for the market’s likely growth trajectory over the forecast period from 2018 to 2023.
Market Synopsis of Global Medical Writing Market
Increasing demand for regulatory paperwork in the pharmaceutical and biopharmaceutical industry is expected to drive the growth of the medical writing market. Pharmaceutical medical writing has grown significantly in India in last few years. Medical writing includes preparing regulatory paperwork and publication of documents related to health, diseases, and healthcare products. It requires medical knowledge and understanding of drug development and regulatory guidelines. Medical writing plays a vital role in the success of a clinical research project. An increase in healthcare spending is expected to drive the growth of the global medical writing market.
Strategic mergers & acquisitions are also projected to boost market growth with companies looking to strengthen their market positions and expand their product portfolios. For instance, in May 2019, ICON acquired MediNova, an integrated network of clinical research sites across Europe, Middle East & Africa. The acquisition helped ICON strengthen its position exponentially in the medical writing market.
The Global Medical Writing Market Size is expected to cross USD 3.25 Billion by 2025 at a CAGR of 10.1 %.
An increase in research and development (R&D) investment and the expiration of patents are directly linked to the growth of the market.
Segmentation
The global medical writing market has been segmented based on type, application, and end user.
The market, based on type, has been divided into clinical writing, regulatory writing, scientific writing, disease- and drug-related writing, and others. The clinical writing segment is likely to be the largest during the review period due to increasing investment made by pharmaceutical industries, and other government bodies are investing in clinical trials globally. The regulatory writing segment is predicted to be the fastest-growing. Regulatory writing includes different clinical documents which include treatment of various disorders and contains descriptions of clinical trials.
The global medical writing market has been segregated, based on application, into medical journalism, medical education, and medico marketing. The medical journalism segment is expected to hold the majority share of the market. It is one of the most significant segments due to the growing need for multiple reliable sources of medical information and update on current treatment methodologies in the drug industry. The medical education segment is expected to be the fastest-growing due to the increasing use of various medical notebooks and online research articles to analyze multiple chronic disorders.
The end user segments of the market are pharmaceutical & biotechnology companies and contract research organizations (CROS). The pharmaceutical & biotechnology companies segment is expected to hold the largest share of the market as the use of medical writing is highest in pharmaceutical companies.
Regional Analysis 
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of medical writing and rising per capita healthcare expenditure. The medical writing market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European medical writing market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The medical writing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of medical writing and rising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The medical writing market in the Middle East & Africa has been divided into the Middle East and Africa.
Key players for Global Medical Writing market
Some of the key players in the Global medical writing market are  Cactus Communications (UK), Covance Inc (US), SIRO CLINPHARM (India), IQVIA (US), OMICS International (India), Freyr Solutions (US), SYNCHROGENIX (US), INCLIN, INC (US), and Clinexa Life Sciences Pvt (Australia), and Parexel International Corporation (US). Top of Form
Posted by at No comments:

Global Diabetic Neuropathy Treatment Market 2020 Insights Business Opportunities, Current Trends and Restraints Forecast 2025

Market Scenario:
The Global Diabetic Neuropathy Treatment Market is expected to cross USD 5.80 Billion by 2025 at a CAGR of 5.1%.
Market Synopsis
The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.
Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.
Market Influencer
The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.
Market Drivers
  • Growing global geriatric population.
  • Change in lifestyle habits leading to bad posture, which is increasing the prevalence of diabetic neuropathy disorder.
  • Increasing research and development of new drugs to treat diabetic neuropathy disorder.
  • Rising prevalence of diabetic neuropathy. For example, the prevalence of diabetic neuropathy in the fiscal year 2000 to 2030 will reach up to 366 million people in the US.
  • Rising awareness of advanced treatments for diabetic neuropathy.
  • Launch of a new medication to manage the symptoms of chronic diabetic neuropathy.
Market Restraints
  • High treatment costs.
  • Availability of alternative therapies such as traditional medicine and physiotherapy.
  • Need for specialized equipment to diagnose and treat diabetic neuropathy.
Segmentation
By Disorder
  • Peripheral Neuropathy: The largest segment of the market, peripheral neuropathy afflicts almost 1% of the entire global population and is three times as likely to afflict women than men.
  • Autonomic Neuropathy: This disorder generally afflicts elderly people. As of 2018, about 23 million people in the US had autonomic neuropathy and over a quarter of those afflicted could not perform daily activities.
  • Proximal Neuropathy: It is a rare type of nerve damage that occurs in hip, buttock, or thigh. It typically affects one side of the body and rarely spreads to the other side of the body. About 50% of patients suffering from diabetes have proximal neuropathy.
  • Focal Neuropathy: This focal neuropathy disorder afflicts roughly 3 out of every ten individuals who have diabetes with over 100 million people affected globally.
By Treatment
  • Drugs: The fastest-growing segment of the market, drugs are most widely used for the treatment of diabetic neuropathy. A rise in the number of FDA approvals for drugs to treat diabetic neuropathy is a key factor for the growth of the segment.
  • Transcutaneous Electrical Nerve Stimulation (TENS): The largest segment, TENS is the preferred treatment for many diabetic neuropathies as they reduce inflammation and suppress immune system activity.
  • Others: The other segment includes physiotherapy and electroacupuncture and various other treatment options for diabetic neuropathy.
By End-User
  • Hospitals and Clinics: The largest segment, hospitals, and clinics are usually the primary points for diagnosis, treatment, and rehabilitation of individuals afflicted with diabetic neuropathy. Growing awareness and increasing efficiency of diabetic neuropathy treatment are projected to drive the growth of this segment during the forecast period.
  • Retail Pharmacy: A small segment. This center provides immediate pain relief and rudimentary drugs for diabetic neuropathy.
  • Online Pharmacy: Various drugs are used for the treatment of diabetic neuropathy which can be easily available in online pharmacy.
  • Others: This segment includes home care and senior citizen centers.
By Region
  • Americas: The largest regional market. The prevalence of diabetic neuropathy is high in the Americas. The region also has a well-established healthcare industry. Out of the entire population, around 72.2% people in the US were suffering from diabetic neuropathy in 2017.
  • Europe: An increasing geriatric population is leading to a rise in the number of diabetic neuropathy disorder cases.
  • Asia-Pacific: The fastest-growing regional market. Asia-Pacific is seeing a surge in the number of people afflicted with diabetic neuropathy due to bad posture brought on by lifestyle changes, aging, and genetic predisposition. Diabetic neuropathy is an increasing problem in Asia. Approximately 4000 patients were diagnosed with diabetic neuropathy in Korea in 2017, whereas in Japan, around 298 people were diagnosed with diabetic neuropathy in 2017.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and a very young population.Top of FormBottom of Form
Posted by at No comments:

Lactose Intolerance Treatment Market 2020 Global Market Trends, Share, Size, Growth, Opportunity and Forecast to 2025

Market scenario:
The Global Lactose Intolerance Treatment Market is expected to register a CAGR of 7.10% and reach USD 41,054.4 Million by 2025. Lactose Intolerance treatment is a digestive problem with an impaired ability to digest lactose. Factors such as rising cases of gastrointestinal disorders, increasing awareness about Lactose Intolerance treatment and related complications, and increased prevalence of Lactose Intolerance treatment are the driving forces for the market. However, side-effects associated with supplements is projected to restraint the market during the forecast period (2019-2025).
Market Dynamics
Lactose Intolerance treatment is a medical condition identified by lactase (lactose digesting enzyme) deficiency within the patient’s body. As a result, lactose remains intact and unabsorbed producing various ill-effects such as flatulence, bloating, abdominal pains, and others. There are four types of lactose intolerance, namely, primary lactase deficiency, secondary lactase deficiency, congenital lactase deficiency, and developmental lactase deficiency. Secondary lactase deficiency mainly occurs due to irritable bowel syndrome (IBS), gastroenteritis, Crohn disease, ulcerative colitis, celiac disease, chemotherapy, and antibiotics. As per the study suggested by the Journal of Health, Population, and Nutrition in 2017, the prevalence of Lactose Intolerance treatment was significantly higher in IBS-D patients than in healthy individuals. In this study, some eligible IBS-D patients and healthy individuals were enrolled. In the enrolled individuals, lactose malabsorption was diagnosed by a lactose hydrogen breath test (HBT), and lactose intolerance-related symptoms were monitored for eight hours following lactose administration. It was found that the prevalence of lactose malabsorption was 72% in IBS patients and 60% in healthy individuals.
Segmentation
The global Lactose Intolerance treatment market has been segmented by type of lactose intolerance, treatment, form, and end user. The market, based on type, has been bifurcated into primary lactose intolerance, secondary lactose intolerance, and congenital/developmental lactose intolerance. Based on form, the Lactose Intolerance treatment market has been segregated into food supplements, enzyme lactase supplements, probiotics, and others (combination products and prebiotics). By form, the global Lactose Intolerance treatment market has been segmented into tablets/capsule, powder, and liquid. On the basis of end-user, the market has been divided into home care and hospitals & clinics. 
The food supplements segment, by treatment is estimated to hold a share of 70.4% in the market.
Regional Analysis
The global Lactose Intolerance treatment market, on the basis of region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Europe held the major market share of 42.0% in 2018. The dairy consumption in Western Europe is good in comparison to other regions of Europe and has a high per-capita consumption rate throughout the region. The Americas held the second largest market share of 28% in 2018. It is further segmented into North and Latin America. The consumption of dairy products is also distinct and variable in the Americas. Latin America, for example, is one of the fastest-growing dairy markets in the world. Consumers in this region are looking for more convenient ways to shop. They seek to purchase products from a single location or store, and it is one of the main drivers of hypermarkets and supermarkets in Latin America. Asia-Pacific is the third-largest region and held the market share of 20.0% in 2018. In terms of value, it has the largest dairy consumption, but it has the lowest per capita income spent on dairy products as it is still developing better infrastructure for the distribution of chilled dairy products. The Middle East and Africa is highly obsolescence with per capita spend on dairy at just USD 25 per head, the lowest in the world.
Key Players
The prominent players in the global are Abbott Laboratories, Inc. (US), Nestle (Switzerland), Cargill, Incorporated (US), Dean Foods (US), Johnson & Johnson, Inc. (US), and Novozyme, (Denmark) are some of the major players in the market.
Some of the key strategies followed by players operating in the global Lactose Intolerance treatmentmarket were innovation, product development, and acquisition & mergers.
  • In March-2018, Nestlé completed its acquisition of Atrium Innovations Inc., a global leader in nutritional health products. This acquisition supports Nestlé’s pursuit of growth opportunities in consumer healthcare to complement the company’s focus on its high-growth food and beverage categories
  • In April-2017, Abbott introduced science-based nutrition drinks to help patients have a better recovery from surgery. New Ensure Surgery Immunonutrition Shake and Ensure Pre-Surgery Clear Nutrition Drink is designed for hospitals implementing surgical guidelines for enhancing patient recovery. These drinks are also lactose-free.
  • In May,2016- Dean Foods launched a new DairyPure brand, lactose free milk to its line of dairy products. DairyPure lactose-free milk delivers real dairy nutrition and delicious taste. Also, it is 100% lactose-free, making it easy to digest for those with lactose sensitivities.
Posted by at No comments:

2020 Latest Study explores the Medical Smart Textile Market Witness Highest Growth in near future by 2027

Market Insights:
The Global Medical Smart Textile Market is expected to register a CAGR of 7.51% to reach 2,105.32 Million by 2027. Medical smart textile is a new field of research and is most widely used in the healthcare sector. Sensors are integrated into the textiles, in continuous contact with the human body, and could capture physiological changes occurring within the body. The demand for medical smart textiles is increasing due to the rising burden of diseases, evolving methods of diagnosis, and extensive use of wearable medical devices. These factors are expected to fuel the growth of the global medical smart textile market. However, the high cost of smart textiles is anticipated to hamper the market growth.
Key Players
The global medical smart textile market overview by Market research Future contains The top prominent players like Schoeller Switzerland, Vista Medical Ltd, Sensoria Inc., Gentherm, Siren, Pireta, AiQ Smart Clothing, Camira Fabrics, Carre Technologies Inc, and 3teks.
Some of the key strategies followed by players operating in the global medical smart textile market were innovation, product development, and acquisition & mergers.
  • In February 2019, Gentherm signed a partnership agreement with ThermoAnalytics, Inc., a leading thermal modeling software development firm for the advancement of human thermal comfort predictions.
  • In June 2019, Pireta developed a unique process that adds conductive metallic pattern directly into textile clothing without changing the fabric feel. These wearable smart garments and e-textile enabled physicians to diagnose diseases in their early stages and provide better treatment options. The launch of this device would help the company to increase its revenue in the future.
  • In July 2019, Camira Fabric acquired Luna Textiles, a US-based company that manufactures fabric for healthcare, hospitality, and other lounge seating purposes. This acquisition helped Camira Fabric to increase its revenue.
Market Dynamics
The rising burden of diseases is expected to fuel the growth of the global medical smart textile market during the forecast period. According to the Global Burden of Disease Study in 2017, from 1990 to 2017, the leading causes of premature deaths were neonatal disorders, ischemic heart disease, lower respiratory infections, diarrhea, chronic obstructive pulmonary disease (COPD), and strokes. These diseases accounted for more than 1 million deaths worldwide in 2017. Additionally, the Global Burden of Disease Study in 2017, stated that there was a change in the mortality rate due to excess drug-resistant tuberculosis from 2007 to 2017.
Segmentation
The global medical smart textile market has been segmented by technology, application, and end user. The market, based on technology, has been divided into wearable technology, textile sensors, and others. Based on application, the medical smart textile market has been segregated into bio-monitoring, surgery, therapy, and wellness and others. The global medical smart textile market, based on end user, has been bifurcated into hospitals and clinics and others. The hospitals and clinics held a share of 67.3% in 2018.
Regional Market Summary
The global medical smart textile market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to dominate the global medical smart textile market. The growth in this region can be attributed to the extensive use of medical devices. Moreover, applications in medical engineering for monitoring vital health indicators help in maximizing the growth of the market in this region. Europe held a substantial share in the global medical smart textile market. This can be attributed to the rising government expenditure to promote the healthcare sector in the region. For instance, according to Eurostat, in 2016, healthcare expenditure per person was EUR 5,000 or higher in three EU member states that are Luxembourg (EUR 5,600), Sweden (EUR 5,100) and Denmark (EUR 5,000), as the per-person healthcare expenditure is very high in Europe and is continuously growing. Asia-Pacific is estimated to be the fastest-growing region in the global market. This is due to the extensive demand for advanced medical devices and increasing applications of technology in the early diagnosis of diseases fueling the growth of the medical smart textile market in the region. The medical smart textile market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2027. The Middle East would lead the market growth in this region. Increasing awareness about medical smart textiles is expected to drive market growth during the assessment period.
Posted by at No comments:

Global Implantable Cardioverter Defibrillator (ICD) Market 2020 by manufacturers, Demand, application, and region 2025

Market Synopsis
The Global Implantable Cardioverter Defibrillator (ICD) Market: Increasing prevalence of cardiovascular diseases, growing aging population, and changing lifestyles are projected to boost the market from USD 6,952.2 Million in 2018 to 10,425.96 Million by 2025 at a CAGR of 5.96%.
Top Key Players
Top Implantable Cardioverter Defibrillator (ICD) Market Manufacturers in the Global market are Abbott Laboratories (US), BIOTRONIK (Germany), Boston Scientific Corporation (US), Medtronic (Ireland), MicroPort Scientific Corporation (China), Koninklijke Philips N.V. (Netherlands), Nihon Kohden Corporation (Japan), Progetti Srl (Italy), Fukuda Denshi Co., Ltd (Japan), Getinge (Sweden), ZOLL Medical Corporation (US), etc.
Market Highlights
According to MRFR analysis, the global implantable cardioverter defibrillator (ICD) market is expected to register a CAGR of 5.96% during the forecast period of 2019 to 2025. Implantable Cardioverter Defibrillator (ICD) is used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart. Factors such as the growing aging population, changing lifestyles such as smoking and alcohol consumption, and the increase in demand for cardiac implants are responsible for the increasing prevalence of cardiac arrhythmias globally. This is likely to fuel the growth of the ICD market during the forecast period. In addition to this, improving efficacy of ICDs for the treatment of cardiac diseases over a period will also fuel the market. According to the American Heart Association, approximately 1.5 million cases of myocardial infarction occur annually, and the incidence rate is approximately 600 cases per 100,000 people in the US. According to the American College of Cardiology Foundation, sudden cardiac arrest (SCA) is also one of the leading causes of death worldwide and is responsible for 250,000 to 450,000 deaths per year in the US. Also, coronary artery disease is a major risk factor for sudden cardiac arrest (SCA).
The global implantable cardioverter defibrillator (ICD) market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen their market positions. For instance, in May 2019, the US Food and Drug Administration (FDA) has approved Boston Scientific's Emblem S-ICD that is used in the treatment of cardiovascular diseases. Through this approval, Boston Scientific focuses on strengthening its position in the US ICD market. Medtronic is developing Extravascular (EV) ICD system, an innovative subcutaneous ICD that is designed to terminate arrhythmias, post-shock pacing to protect from sudden cardiac arrest, and temporary back-up bradycardia pacing.
Segmentation
By Type
  • Regular ICD: Holdsthe highest share in the market due to the increasing occurrences and growing incidence rates of autoimmune diseases.
  • Cardiac Resynchronization Therapy Defibrillators (CRT-D): Holds the second-largest share in the market and is expected to grow at a moderate rate during the forecast period. The growth is mainly due to increasing cardiac arrests among patients, R&D by major players, and strategic partnerships
  • Subcutaneous-ICD (S-ICD): Holds the third-largest share in the market and is expected to grow at a steady rate in the market during the forecast period. New product launches, manufacturing facility expansion in emerging countries such as India, China, Brazil, and other emerging countries could drive the market.
  • Others: Covers accessories and small component parts of implantable cardioverter defibrillators. This segment holds the least share in the market.
By Indication
  • Myocardial Ischemia: Myocardial Ischemia is the largest as well as the fastest-growing segment by indication as ICDs are majorly used in the treatment of myocardial ischemia. Moreover, the prevalence rate of sudden cardiac arrests is rising. Myocardial ischemia is further segmented into symptomatic and asymptomatic.
  • Acute Myocardial Infarction: It is the second-largest segment in the market, and this condition is also commonly called a heart attack. Acute myocardial infarction is a life-threatening condition that occurs when blood flow to the heart muscle is abruptly cut off, causing tissue damage. It is the second-largest segment in the market by indication.
  • Electrolyte Imbalance and Drug Toxicity: It is the third-largest and fastest-growing segment in the market.
By End User
  • Hospitals & Clinics: This is the largest and fastest-growing market segment and is projected to grow well beyond the forecast period. Hospitals and clinics are primary care centers for individuals afflicted with type-1 diabetes and are also cost-effective. Moreover, in countries with government-funded healthcare and a high prevalence of type-1 diabetes, hospitals and clinics are the main treatment centers, which drives the growth of the segment.
  • Ambulatory Surgical Centers: A more specialized treatment option, a large number of specialty centers have established across the US and are being opened in developing nations such as India and China. This segment is growing due to the increased number of individuals afflicted with the condition and the higher returns on investment from specialty centers as compared to hospitals and clinics.
  • Others: The ease of availability and delivery of diabetes medication has led to patients opting for home treatment. The segment also covers old age homes as the geriatric population is highly susceptible to type-1 diabetes. The segment is expected to grow as awareness regarding the condition increases along with the ease of treatment.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICD market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The ICDs market in the Americas is likely to hold a major share owing to the increased patient pool. The European ICD market has been sub-divided classified as Western Europe and Eastern Europe. The Western European market has further been classified categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ICD market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific ICD market is projected to be the fastest-growing due to the increasing incidences of acute myocardial infarction and myocardial infraction, growing aging population, and changing lifestyle (smoking and alcohol consumption) in the region. The ICD market in the Middle East & Africa has been divided into the Middle East and Africa.
Posted by at No comments:
Subscribe to: Posts (Atom)